S&P Futures
6,000.75 -5.75 (-0.10%) Dow Futures
44,799.00 -27.00 (-0.06%) Nasdaq Futures
20,876.50 -3.75 (-0.02%) Russell 2000 Futures
2,435.20 -15.80 (-0.64%) Crude Oil
69.13 +0.19 (+0.28%) Gold
2,615.10 -3.40 (-0.13%)
Karolinska Development AB (publ) (KDEV.ST)
| Previous Close | 1.0340 |
| Open | 1.0380 |
| Bid | 1.0100 x 0 |
| Ask | 1.0240 x 0 |
| Day's Range | 1.0000 - 1.0380 |
| 52 Week Range | 0.9500 - 1.9480 |
| Volume | |
| Avg. Volume | 292,874 |
| Market Cap | 273.611M |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | Feb 14, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.40 |
GlobeNewswireKarolinska Development's portfolio company Modus Therapeutics secures bridge financing
STOCKHOLM, SWEDEN November 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has secured access to bridge financing of up to SEK 5 million from Karolinska Development, the company’s largest shareholder. The funding enables Modus to initiate the recently approved phase 2a study in chronic kidney disease. ”Modus Therapeutics research is gaining momentum and with this funding they now have the opportunity to maintain a good pa
- GlobeNewswire
Karolinska Development’s portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study
STOCKHOLM, SWEDEN – November 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present data from a recent interim analysis from an ongoing Phase 1b/2a clinical study of golexanolone in patients with Primary Biliary Cholangitis. The preliminary results show that golexanolone was well-tolerated and achieved drug exposure levels that correlate to clinical treatment doses. The results will be presented at the Late Breaking
